<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1216">
  <stage>Registered</stage>
  <submitdate>22/06/2006</submitdate>
  <approvaldate>22/06/2006</approvaldate>
  <nctid>NCT00343980</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes</studytitle>
    <scientifictitle>Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN1998-1682</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - rosiglitazone
Treatment: drugs - inhaled human insulin
Treatment: drugs - glimepiride

Experimental: A - 

Active Comparator: B - 


Treatment: drugs: rosiglitazone
Tablets, 4 mg once or twice a day.

Treatment: drugs: inhaled human insulin
Treat-to-target dose titration scheme, pre-prandial, inhalation.

Treatment: drugs: glimepiride
Tablets, 4 mg/day.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment difference in HbA1c</outcome>
      <timepoint>After 26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint>For the duration of the trial</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body weight</outcome>
      <timepoint>during treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung function</outcome>
      <timepoint>after 26 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose</outcome>
      <timepoint>after 26 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hypoglycaemia</outcome>
      <timepoint>from 12-26 weeks of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes

          -  Treated with OAD(s) for more than or equal to 2 months

          -  Body mass index (BMI) less than or equal to 40.0 kg/m2

          -  HbA1c greater than or equal to 8.0 % and less than or equal to 11.0 % for subjects in
             OAD monotherapy

          -  HbA1c greater than or equal to 7.5 % and less than or equal to 10.0 % for subjects on
             OAD combination therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Recurrent major hypoglycaemia

          -  Current smoking or smoking within the last 6 months

          -  Impaired hepatic or renal function

          -  Cardiac problems

          -  Uncontrolled hypertension

          -  Proliferative retinopathy or maculopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>10/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>363</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>10/03/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - St Leonards</hospital>
    <hospital>Novo Nordisk Investigational Site - Wollongong</hospital>
    <hospital>Novo Nordisk Investigational Site - Garran</hospital>
    <hospital>Novo Nordisk Investigational Site - Kingswood</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>2747 - Kingswood</postcode>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Osijek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Coimbatore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <state>Skopje</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bornova-IZMIR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Bursa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Asia, Europe and Oceania. The aim of this research study is to
      compare the efficacy of adding inhaled preprandial insulin to glimepiride compared to adding
      rosiglitazone to glimepiride for the treatment of type 2 diabetes and to verify its safety
      (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00343980</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>